Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Advertising Studies Will Examine Website Formatting, Patient Testimonials, Outside Links

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will examine how various aspects of Internet-based ads affect consumer understanding of product safety and efficacy in four separate studies.

You may also be interested in...



FDA’s Biggest DTC Advertising Study Eyes Online Promotion

The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.

Pharma Companies Starting To Build Dedicated Digital Marketing/Social Media Staffs

Despite an uncertain regulatory environment and no clear way to link digital marketing and social media activities to revenues, pharmaceutical companies are starting to spend more on promotional activities in the digital realm compared to traditional media (TV/radio/print advertising) and are building dedicated staffs to support these activities.

FDA Proposals For Studying Internet Promotions Raise Concerns

FDA should not delay draft guidance on Internet and social media promotional activities while it studies how consumer understanding of a drug’s safety and efficacy is affected by the techniques used to present information on branded websites, according to comments on the proposed studies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel